Navigation Links
Study Finds Surfacide UV-C Light Effective as an Adjunct to Infection Control in a Pediatric Burn Hospital
Date:3/27/2017

WAUKESHA, Wis., March 27, 2017 /PRNewswire/ -- A recent study at Shriners Hospitals for Children –  Cincinnati, one of only four freestanding hospitals in the country dedicated to the treatment of pediatric burns and specializing in plastic and reconstructive surgery, concluded that the Surfacide Helios® UV-C Disinfection System is "…an effective and integral component in reducing bacterial pathogens not killed by the EVS (manual) cleaning process alone." The findings were published at the American Burn Association's 49th Annual Meeting in Boston earlier this week. The authors discussed their findings from 234 cultures obtained from rooms and noted a 37 percent organism reduction from terminal cleaning alone. When the Surfacide UV-C Disinfection System was used in addition to the EVS terminal cleaning process, the authors reported a "total elimination of pathogens."

"Surfacide's Helios system incorporates three UV-C energy emitting towers in the patient environment to eradicate drug-resistant organisms, including superbugs such as C. Diff, MRSA, VRE, CRE and Acinetobacter," said Gunner Lyslo, founder and CEO of Surfacide, LLC.  "The system has been shown in studies to significantly reduce the risk of HAIs and lower hospital infection rates." 

Continue Reading
Surfacide Helios(R) UV-C Disinfection System
Surfacide Helios(R) UV-C Disinfection System

The 10-to-20 minute Surfacide disinfection cycle is performed in an unoccupied room, after an environmental services cleaning professional has manually cleaned the area and wiped down surfaces. Treating the room with UV-C energy is an evidence-based disinfection modality disinfecting areas that were not completely cleaned manually.

Other competing systems use just one tower, which is a less effective approach. Single emitter systems, including pulsed xenon gas systems, cannot reach all high-touch surfaces in a single disinfection cycle. Surfacide's multiple emitter approach disinfects an entire room in just one cycle, including the bathroom and other hard-to-reach areas more quickly and effectively. The Helios emitters are positioned closer to hard surfaces, thereby reducing UV-C disinfection time and improving overall efficacy.

Healthcare providers are turning to UV-C technology as a complement to traditional cleaning methods to combat healthcare-associated infections (HAIs). UV-C energy (at 254nm) is the peak germ-killing part of the ultraviolet spectrum.

According to the CDC, roughly one in every 20 hospitalized patients acquires an infection during the course of receiving treatment for another condition. HAIs create significant health risks and cost the healthcare industry billions of dollars each year. That toll has placed a high priority on innovative technologies such as UV-C disinfection.

The Surfacide Helios system is available in the U.S. and internationally. For more information as well as efficacy studies, visit Surfacide.com or call 844-390-3538.

About Surfacide
Surfacide provides an evidence-based, automatic UV-C room disinfection system that eradicates multi-drug resistant organisms, including C.Diff, MRSA, VRE, CRE and Acinetobacter. The Surfacide Helios® system implements three emitters into the patient environment to clean all areas of the patient room, including the bathroom and other hard-to-reach areas.  

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-finds-surfacide-uv-c-light-effective-as-an-adjunct-to-infection-control-in-a-pediatric-burn-hospital-300429816.html


'/>"/>
SOURCE Surfacide
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and which He does not. Yisrayl says with so many titles and names for ... but he says with a little Scripture, backed with a lot of research, the truth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
Breaking Medicine News(10 mins):